Clinical Trial Update: Effects of RM-493 on Energy Expenditure in Obese Individuals [Phase 1]

View source ↗

Summary

Phase 1 trial assessing the effects of RM-493 on energy expenditure in obese individuals has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity
• Obesity

Drugs mentioned

• setmelanotide (RM-493) (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Obesity, Morbid Obesity | Phase 1 | Status: COMPLETED